Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study

Jacoba M. Maurer*, Susan Hofman, Reinout C. A. Schellekens, Wouter F. Tonnis, Annelien O. T. Dubois, Herman J. Woerdenbag, Wouter L. J. Hinrichs, Jos G. W. Kosterink, Henderik W. Frijlink

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: ArticleAcademicpeer review

17 Citaten (Scopus)


The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.

Originele taal-2English
Pagina's (van-tot)175-186
Aantal pagina's12
TijdschriftInternational Journal of Pharmaceutics
Nummer van het tijdschrift1-2
StatusPublished - 30-mei-2016

Citeer dit